test

Patient & Cancer Information | Our Experts | Expert Profiles

Nina Kadan-Lottick MD

Associate Professor of Pediatrics (Hematology / Oncology); Medical Director, HEROS Program

Clinical Interests

Late effects of cancer therapy, including osteoporosis, growth failure, neurocognitive deficits, infertility, cardiomyopathy, and second neoplasms; Childhood cancer survivorship; Treatment of acute childhood leukemia and other childhood malignancies; Diagnosis and treatment of hypoglobinopathies; Quality of life of childhood cancer patients; Sarcomas; lymphoma; Brain tumors; Blood disorders; Thrombocytopenia; Hematologic disorders; Immune hematologic disorders

Board Certifications

2000
Hematology-Oncology, Board Certified

Patient Care Locations

nina_kadan-lottickfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Leukemia and Down SyndromeStudy of Blood Samples From Newborns With Down Syndrome
Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma, Mixed Childhood Rhabdomyosarcoma, Pleomorphic Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, and Recurrent Childhood RhabdomyosarcomaVinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma, Mixed Childhood Rhabdomyosarcoma, Pleomorphic Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, and Recurrent Childhood RhabdomyosarcomaVinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Fungal Infection, Leukemia, and NeutropeniaCaspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy
Recurrent or Refractory Solid TumorsA Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors (ADVL1221)

Edit Profile